Scarica l'app Stockscreener
36.71
1.37%
-0.51
Dopo l'orario di chiusura:
36.71
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HRMY Giù?
Forum
Previsione
Precedente Chiudi:
$37.22
Aprire:
$36.92
Volume 24 ore:
468.34K
Relative Volume:
0.72
Capitalizzazione di mercato:
$2.11B
Reddito:
$681.88M
Utile/perdita netta:
$122.63M
Rapporto P/E:
17.40
EPS:
2.11
Flusso di cassa netto:
$220.18M
1 W Prestazione:
+0.77%
1M Prestazione:
+14.50%
6M Prestazione:
-3.42%
1 anno Prestazione:
+11.85%
Intervallo 1D:
$36.54
$37.11
Intervallo di 1 settimana:
$35.04
$37.27
Portata 52W:
$26.47
$41.61
Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile
Nome
Harmony Biosciences Holdings Inc
Settore
Industria
Telefono
(484) 539-9800
Indirizzo
630 W GERMANTOWN PIKE, PLYMOUTH MEETING
Confronta HRMY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HRMY
Harmony Biosciences Holdings Inc
|
36.71 | 2.14B | 681.88M | 122.63M | 220.18M | 2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-07-10 | Ripresa | Goldman | Neutral |
| 2025-06-02 | Ripresa | Oppenheimer | Outperform |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-12-17 | Iniziato | H.C. Wainwright | Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-09-10 | Iniziato | UBS | Buy |
| 2024-06-21 | Iniziato | Citigroup | Buy |
| 2024-01-02 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-09-25 | Downgrade | Goldman | Neutral → Sell |
| 2023-09-07 | Iniziato | Berenberg | Buy |
| 2023-04-20 | Iniziato | BofA Securities | Neutral |
| 2022-10-14 | Aggiornamento | Janney | Neutral → Buy |
| 2022-10-14 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-08-03 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-13 | Downgrade | Goldman | Buy → Neutral |
| 2022-07-07 | Iniziato | Mizuho | Buy |
| 2022-04-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-12-01 | Iniziato | Oppenheimer | Outperform |
| 2021-11-04 | Iniziato | Raymond James | Outperform |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2021-03-29 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-09-14 | Iniziato | Goldman | Neutral |
| 2020-09-14 | Iniziato | Jefferies | Buy |
| 2020-09-14 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Harmony Biosciences Holdings Inc Borsa (HRMY) Ultime notizie
How high can Harmony Biosciences Holdings Inc. stock price go in 2025Free Stock Market Query - jammulinksnews.com
Harmony Biosciences to Report Second Quarter 2025 Financial Results on August 5, 2025 - MarketScreener
Is Harmony Biosciences Holdings Inc. a good long term investmentAccelerated investment success - Autocar Professional
Harmony Biosciences Advances Pipeline While Navigating Analyst Caution - Insider Monkey
Harmony Biosciences Holdings Inc. Stock Analysis and ForecastBreakout stock performance - jammulinksnews.com
What analysts say about Harmony Biosciences Holdings Inc. stockBreakout profit opportunities - jammulinksnews.com
What drives Harmony Biosciences Holdings Inc. stock priceMarket-crushing profits - jammulinksnews.com
Harmony Biosciences to Report Second Quarter 2025 Financial Resu - GuruFocus
13 Best Low Risk High Growth Stocks to Buy - Insider Monkey
Truist Securities initiates Harmony Biosciences stock with Buy rating - Investing.com Australia
Truist Securities initiates Harmony Biosciences stock with Buy rating By Investing.com - Investing.com UK
Truist Securities Initiates Coverage on Harmony Biosciences (HRM - GuruFocus
H.C. Wainwright reiterates Buy rating on Harmony Biosciences stock - Investing.com
Truist Securities Starts Harmony Biosciences Holdings Inc. (HRMY) at Buy - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Harmony Biosciences Holdings Inc. (HRMY) - StreetInsider
Truist Initiates Buy Rating for Harmony Biosciences (HRMY) with Promising Growth Prospects | HRMY Stock News - GuruFocus
Why Harmony Biosciences (HRMY) is Poised to Beat Earnings Estimates Again - MSN
Transcript : Harmony Biosciences Holdings, Inc. Presents at H.C. Wainwright "HCW@Home" Series, Jul-17-2025 10 - MarketScreener España
Harmony Biosciences Balances Growth Potential With Clinical Milestones - Finimize
Harmony Biosciences to Participate in H.C. Wainwright HCW@Home Series - MarketScreener
When (HRMY) Moves Investors should Listen - news.stocktradersdaily.com
Analysts Offer Insights on Healthcare Companies: Senseonics Holdings (SENS) and Harmony Biosciences Holdings (HRMY) - The Globe and Mail
Mizuho Reaffirms “Outperform” on Harmony Biosciences (HRMY) for BP1.15205 Data - MSN
Harmony Biosciences to Participate in H.C. Wainwright "HCW@Home" Series - BioSpace
3 Reasons Growth Investors Will Love Harmony Biosciences (HRMY) - Yahoo Finance
Is Harmony Biosciences (HRMY) Stock Undervalued Right Now? - Yahoo Finance
Does Harmony Biosciences (HRMY) Have the Potential to Rally 43.19% as Wall Street Analysts Expect? - Zacks Investment Research
Harmony Biosciences to Participate in H.C. Wainwright "HCW@Home" Series | HRMY Stock News - GuruFocus
Harmony Biosciences CEO to Share Latest Company Updates at Exclusive H.C. Wainwright Virtual Conference - Stock Titan
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Harmony Biosciences Holdings, Inc. (HRMY) - ACCESS Newswire
Most Volatile Stocks in the US (July 2025) - Investing.com
Harmony Biosciences Reaches Settlement with Lupin Over WAKIX® Patent Litigation - MSN
Harmony Biosciences Preclinical Data for Narcolepsy Drug BP1.15205 Shows Promise - MSN
Harmony Biosciences stock resumes coverage at Goldman Sachs with Neutral rating - Investing.com Canada
Goldman Sachs Resumes Harmony Biosciences Holdings Inc. (HRMY) at Neutral - StreetInsider
6 Analysts Assess Harmony Biosciences Hldgs: What You Need To Know - Benzinga
Harmony Biosciences (HRMY) Maintains Buy Rating with Price Targe - GuruFocus
Harmony Biosciences Holdings Inc Azioni (HRMY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.32%
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):